Clinical research of Ganshuang granules on cirrhotic patients following chronic hepatitis B

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034262

Enrollment

Unknown

Registered

2020-06-30

Start date

2017-02-01

Completion date

Unknown

Last updated

2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepaticsclerosis

Interventions

Case series:took Ganshuang granules orally

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Guidelines for the prevention and treatment of chronic hepatitis B (2015)

Exclusion criteria

Exclusion criteria: Hepatitis A, C or D virus infection; Immune hepatitis, drug hepatitis, steatohepatitis; Combined with severe dysfunction of heart, lung, kidney, brain or other organs; Combined with malignant tumor or mental disease.

Design outcomes

Primary

Measure	Time frame
ALT, AST, Alb, TBil, HA, C?, PCIII, LN, Th17/Treg;	—

Countries

China

Contacts

Public ContactCHEN Fang-fang

The Affiliated Hospital of Northwest Minzu University

124445576@qq.com+86 18109497035

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026